Literature DB >> 15455181

Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: the Tromso study 2001.

Ingeborg Hartz1, Anne Elise Eggen, Sameline Grimsgaard, Frode Skjold, Inger Njølstad.   

Abstract

OBJECTIVE: The beneficial effect of lipid-lowering drugs (LLDs) is well documented. Despite increasing sales of LLDs, little is known about what characterizes LLD users. Our objective was to describe LLD users in a general population according to socio-demographic factors, cardiovascular risk factors and coronary heart disease (CHD), and to study the achievement of cholesterol treatment goals according to national guidelines.
METHODS: The Tromso study is a population-based study of chronic diseases, risk factors and drug use in the municipality Tromso, in north Norway. The fifth survey was conducted in 2001 and included 7,973 men and women (attendance rate 78.1%). Self-reported use of LLDs and/or proprietary LLDs was included as LLD use in the analysis.
RESULTS: LLD use was reported in 9.6% of all women and 14.0% of all men, of whom 36.5% achieved the nationally recommended lipid goal. Among individuals with CHD, 49.9% of all women and 55.4% of all men were LLD users. The individuals with a risk condition (hypertension and/or diabetes) and total cholesterol level above the target of 5.0 mmol/l and the healthy individuals with total cholesterol level >/=8.0 mmol/l constituted 47.2% of the study population without CHD. In this group, which was eligible for primary prevention, 8.0% of the women and 7.4% of the men reported LLD use.
CONCLUSIONS: Only half of all subjects with CHD were taking a LLD. The large discrepancy between national recommendations and actual LLD use in primary prevention should be addressed in future revisions of the guidelines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15455181     DOI: 10.1007/s00228-004-0827-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  35 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

2.  Use of lipid-lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden.

Authors:  N Magrini; T Einarson; A Vaccheri; P McManus; N Montanaro; U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.

Authors: 
Journal:  Eur Heart J       Date:  2001-04       Impact factor: 29.983

5.  Use and monitoring of "statin" lipid-lowering drugs compared with guidelines.

Authors:  S A Abookire; A S Karson; J Fiskio; D W Bates
Journal:  Arch Intern Med       Date:  2001-01-08

6.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

Authors:  P Jones; S Kafonek; I Laurora; D Hunninghake
Journal:  Am J Cardiol       Date:  1998-03-01       Impact factor: 2.778

7.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

8.  Is questionnaire information valid in the study of a chronic disease such as diabetes? The Nord-Trøndelag diabetes study.

Authors:  K Midthjell; J Holmen; A Bjørndal; G Lund-Larsen
Journal:  J Epidemiol Community Health       Date:  1992-10       Impact factor: 3.710

9.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  8 in total

1.  Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors.

Authors:  Mohammad Abu Zaid; Wambui G Gathirua-Mwangi; Chunkit Fung; Patrick O Monahan; Omar El-Charif; Annalynn M Williams; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Ryan Cook; Sandra K Althouse; Shirin Ardeshir-Rouhani-Fard; Paul C Dinh; Howard D Sesso; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis
Journal:  J Natl Compr Canc Netw       Date:  2018-03       Impact factor: 11.908

2.  Primary care of patients with high cardiovascular risk : Blood pressure, lipid and diabetic target levels and their achievement in Hungary.

Authors:  Endre Szigethy; Zoltán Jancsó; Csaba Móczár; István Ilyés; Eszter Kovács; László Róbert Kolozsvári; Imre Rurik
Journal:  Wien Klin Wochenschr       Date:  2013-07-04       Impact factor: 1.704

3.  Cholesterol in women at high cardiovascular risk is less successfully treated than in corresponding men. The Skaraborg Hypertension and Diabetes Project.

Authors:  Anita Mehner; Ulf Lindblad; Lennart Råstam; Kristina Bengtsson Boström
Journal:  Eur J Clin Pharmacol       Date:  2008-04-04       Impact factor: 2.953

4.  Which population groups should be targeted for cardiovascular prevention? A modelling study based on the Norwegian Hordaland Health Study (HUSK).

Authors:  Mette Brekke; Magne Rekdal; Jørund Straand
Journal:  Scand J Prim Health Care       Date:  2007-06       Impact factor: 2.581

5.  Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education.

Authors:  Randi Selmer; Solveig Sakshaug; Svetlana Skurtveit; Kari Furu; Aage Tverdal
Journal:  Br J Clin Pharmacol       Date:  2008-12-10       Impact factor: 4.335

6.  Implementing the European guidelines for cardiovascular disease prevention in the primary care setting in Cyprus: lessons learned from a health care services study.

Authors:  Theodora Zachariadou; Henri E J H Stoffers; Costas A Christophi; Anastasios Philalithis; Christos Lionis
Journal:  BMC Health Serv Res       Date:  2008-07-16       Impact factor: 2.655

7.  Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study.

Authors:  Ingeborg Hartz; Solveig Sakshaug; Kari Furu; Anders Engeland; Anne Elise Eggen; Inger Njølstad; Svetlana Skurtveit
Journal:  BMC Clin Pharmacol       Date:  2007-12-05

8.  Evaluating an implementation strategy in cardiovascular prevention to improve prescribing of statins in Germany: an intention to treat analysis.

Authors:  Heidemarie Keller; Oliver Hirsch; Petra Kaufmann-Kolle; Tanja Krones; Annette Becker; Andreas C Sönnichsen; Erika Baum; Norbert Donner-Banzhoff
Journal:  BMC Public Health       Date:  2013-07-02       Impact factor: 3.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.